Samsung Biologics receives 2022 CMO Leadership Award in all six categories

08 February 2022 | Tuesday | News


- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), announced that it has been selected as a winner of the 2022 CMO Leadership Awards presented by Outsourced Pharma and Life Science Leader. Samsung Biologics received a total of six CMO Leadership Awards across all performance categories: capabilities, compatibility, expertise, reliability, quality, and service

Now in its 11th year, the CMO Leadership Awards offer accurate and reliable customer feedback to provide support in choosing a reputable partner for development and manufacturing needs within the biopharmaceutical and pharmaceutical industry. Since 2013, Samsung Biologics has been recognized in the CMO Leadership Awards for nine consecutive years.

"We are incredibly proud to receive this distinction across all six performance categories, especially at this pivotal moment in healthcare when it is more crucial than ever to successfully supply medicines to our clients and save the lives of patients," said John Rim, President and CEO of Samsung Biologics. "This recognition reminds us of our responsibility as a trusted CDMO partner to our clients and to respond quickly to the evolving needs in the industry."

"For nearly a decade, these awards have proven most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities," said Louis Garguilo, Chief Editor and Conference Chair of Outsourced Pharma. "Our research arm, Industry Standard Research (ISR), which only surveys drug sponsors who have worked recently with specific CDMOs, ensures the validity of these results. Our winners will be your champions of outsourcing."

Samsung Biologics demonstrated strong operational performance and business agility in 2021 with all Plants 1, 2, and 3 in stable operations. Plant 4 will commence partial operations in Q4 this year with full completion expected mid-next year, and the company will also begin construction of Plant 5 within 2022 where it will offer multi-modal product services in addition to the mRNA vaccine drug substance (DS) manufacturing suite expected to be ready for cGMP operations within the earlier part of this year.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close